Board of Directors | Management | Investors
______________________________________________________________________________________________
In September 2010, CytomX Therapeutics completed a $30 million Series B financing, in a round led by Third Rock Ventures and including Roche Venture Fund.
______________________________________________________________________________________________
|
Third Rock Ventures is a premier venture firm focused on life sciences, investing and launching companies that make a difference in people's lives. Collaborating with entrepreneurs, the Third Rock team applies its deep expertise to establish the roadmap and building blocks for a rapidly growing and highly successful life sciences company. The Third Rock team has a unique vision and experience in building great companies, extensive academic and industry networks and a collective track record for creatively managing the value creation path to deliver exceptional performance. For more information, please visit www.thirdrockventures.com. |
______________________________________________________________________________________________
The Roche Venture fund invests in early stage biotech diagnostics companies to develop commercially successful innovative life science companies. Based in Basel with an office in South San Francisco, the Roche Venture Fund invests globally with a portfolio of over 35 companies in 10 countries. For more information, please visit www.venturefund.roche.com.
